// Definition
MAPS-sponsored research into MDMA-assisted psychotherapy for treatment-resistant PTSD, which was transitioning from phase 2 to phase 3 clinical trials.
// From the Episode
Rick Doblin discussed how MAPS had been pursuing MDMA-assisted therapy for PTSD for decades. By the time of this episode, they were completing international phase 2 pilot studies and transitioning to phase 3 — the key studies needed to make MDMA an FDA-approved medicine. He noted the parallel with psilocybin research for end-of-life anxiety. Unlike marijuana research, MAPS could supply their own MDMA without NIDA interference.